<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37419524</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in an academic tertiary care centre.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e003037</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2023-003037</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the sensitivity and specificity of the 2019 EULAR/American College of Rheumatology (ACR) classification criteria for systemic lupus erythematosus (SLE) in outpatients at an academic tertiary care centre and to compare them to the 1997 ACR and the 2012 Systemic Lupus International Collaborating Clinics criteria.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Prospective and retrospective observational cohort study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">3377 patients were included: 606 with SLE, 1015 with non-SLE autoimmune-mediated rheumatic diseases (ARD) and 1756 with non-ARD diseases (hepatocellular carcinoma, primary biliary cirrhosis, autoimmune hepatitis). The 2019 criteria were more sensitive than the 1997 criteria (87.0% vs 81.8%), but less specific (98.1% vs 99.5% in the entire cohort and 96.5% vs 98.8% in patients with non-SLE ARD), resulting in Youden Indexes for patients with SLE/non-SLE ARD of 0.835 and 0.806, respectively. The most sensitive items were history of antinuclear antibody (ANA) positivity and detection of anti-double-stranded deoxyribonucleic acid (dsDNA) antibodies. These were also the least specific items. The most specific items were class III/IV lupus nephritis and the combination of low C3 and low C4 complement levels, followed by class II/V lupus nephritis, either low C3 or low C4 complement levels, delirium and psychosis, when these were not attributable to non-SLE causes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this cohort from an independent academic medical centre, the sensitivity and specificity of the 2019 lupus classification criteria were confirmed. Overall agreement of the 1997 and the 2019 criteria was very good.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Schmidtmann</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute for Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kraus</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-6351-3706</Identifier><AffiliationInfo><Affiliation>1st Department of Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinmann</LastName><ForeName>Arndt</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1st Department of Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xfc;tz</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>1st Department of Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cla&#xdf;en</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1st Department of Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schleicher</LastName><ForeName>Eva Maria</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>1st Department of Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Boedecker-Lips</LastName><ForeName>Simone Cosima</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>1st Department of Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Weinmann-Menke</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1st Department of Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany Julia.Weinmann-Menke@unimedizin-mainz.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg University, Mainz, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003181">Complement C4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012219" MajorTopicYN="Y">Rheumatology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062606" MajorTopicYN="N">Tertiary Care Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003181" MajorTopicYN="N">Complement C4</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune Diseases</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword><Keyword MajorTopicYN="N">Systemic Lupus Erythematosus</Keyword></KeywordList><CoiStatement>Competing interests: JW-M received honoraria from GlaxoSmithKline, AstraZeneca, Otsuka and Novartis unrelated to this work. DK received honoraria from AstraZeneca and Novartis unrelated to this work. The other authors declare nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>8</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>7</Day><Hour>20</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37419524</ArticleId><ArticleId IdType="pmc">PMC10347496</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2023-003037</ArticleId><ArticleId IdType="pii">rmdopen-2023-003037</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Virchow R. Historische Notizen &#xdc;ber lupus. Archiv f Pathol Anat 1865;32:139&#x2013;43. 10.1007/BF01929020</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01929020</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AS, Canoso JJ. Criteria for the classification of systemic lupus erythematosus--status 1972. Arthritis Rheum 1972;15:540&#x2013;3. 10.1002/art.1780150512</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780150512</ArticleId><ArticleId IdType="pubmed">4117792</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AS, Reynolds WE, Franklin EC, et al. . Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 1971;21:643&#x2013;8.</Citation></Reference><Reference><Citation>Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EM, Cohen AS, Fries JF, et al. . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271&#x2013;7. 10.1002/art.1780251101</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780251101</ArticleId><ArticleId IdType="pubmed">7138600</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai A-M, Alarc&#xf3;n GS, et al. . Derivation and validation of the systemic lupus International collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677&#x2013;86. 10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, et al. . European League against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheum 2019;71:1400&#x2013;12. 10.1002/art.40930</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M. EULAR/ACR classification criteria for SLE. Semin Arthritis Rheum 2019;49:S14&#x2013;7. 10.1016/j.semarthrit.2019.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2019.09.009</ArticleId><ArticleId IdType="pubmed">31779843</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy G, Isenberg DA. Author correction: new therapies for systemic lupus erythematosus - past imperfect, future tense. Nat Rev Rheumatol 2019;15:509. 10.1038/s41584-019-0262-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-019-0262-2</ArticleId><ArticleId IdType="pubmed">31270422</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurman JM. BLISS in the treatment of lupus nephritis. Clin J Am Soc Nephrol 2021;16:969&#x2013;71. 10.2215/CJN.17991120</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.17991120</ArticleId><ArticleId IdType="pmc">PMC8216619</ArticleId><ArticleId IdType="pubmed">33536242</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;Era M, Bruce IN, Gordon C, et al. . Current challenges in the development of new treatments for lupus. Ann Rheum Dis 2019;78:729&#x2013;35. 10.1136/annrheumdis-2018-214530</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214530</ArticleId><ArticleId IdType="pubmed">30636212</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, D&#xf6;rner T, et al. . Advances in SLE classification criteria. J Autoimmun 2022;132:102845. 10.1016/j.jaut.2022.102845</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102845</ArticleId><ArticleId IdType="pubmed">35725680</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan BCH, Tang I, Bonin J, et al. . The performance of different classification criteria for systemic lupus erythematosus in a real-world rheumatology department. Rheumatology (Oxford) 2022;61:4509&#x2013;13. 10.1093/rheumatology/keac120</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac120</ArticleId><ArticleId IdType="pmc">PMC9629341</ArticleId><ArticleId IdType="pubmed">35348630</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Brinks R, D&#xf6;rner T, et al. . European League against rheumatism (EULAR)/American college of rheumatology (ACR) SLE classification criteria item performance. Ann Rheum Dis 2021;80:775&#x2013;81. 10.1136/annrheumdis-2020-219373</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-219373</ArticleId><ArticleId IdType="pubmed">33568386</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>